With Tremfya also securing approval in UC earlier this month, competition promises to be fierce among the IL-23s, according to […]
Newly released data may provide a competitive edge over in-class competitor, Janssen’s Tremfya EXTON, Pa., December 21, 2022 /PRNewswire/ — Spherix
” Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene
” New EU4+UK research reveals a sizable gap between growing physician preference for IL-23 inhibitors and their real-world use in
New offering combines direct healthcare stakeholder input, therapeutic expertise, and AI-enabled execution to help life sciences organizations achieve faster insights.
” Nephrologists say they would nearly triple Xphozah use without access barriers, but Spherix chart data reveal that physicians substantially
” Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific
Early physician experience suggests TYK2 inhibition may expand oral treatment options beyond traditional positioning, with implications for future competitive dynamics
Three-quarters of gastroenterologists and hepatologists report high unmet need for MASH therapies, while access to approved treatments remains limited. EXTON,
Parallel Spherix Global Insights studies reveal expanding biologic use and evolving treatment strategies have yet to fully translate into durable
